Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,835

Document Document Title
WO/2024/055758A1
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...  
WO/2024/059803A1
An oral animal feed and a method of preventing and/or controlling parasitic worms in an mammal in need thereof by orally administering to the mammal, for example a canine, a feed or a composition comprising an effective amount of an anth...  
WO/2024/059333A1
This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular...  
WO/2024/059837A1
An oral animal feed and a method of preventing and/or controlling heartworms in a mammal in need thereof by orally administering to the mammal, for example a canine, a feed comprising an effective amount of a systemic anthelmintic that h...  
WO/2024/054115A1
The disclosure relates to organosulfur compounds and compositions comprising same. In particular, the disclosure relates to Bis(4-fluorophenyl) disulfide, Bis(4- chlorophenyl) disulfide, Bis(4-chlorophenyl) thiosulfinate, Bis(4-fluorophe...  
WO/2024/003331A9
The present invention relates, generally, to beta-lactones comprising a spiro-fused ring and one beta-lactone ring and derivatives thereof, in particular an unprecedented macrolide named spirolactone, and their use as antimicrobial agents.  
WO/2024/047241A1
The present invention relates to compounds and compositions of Formula (I) for treating a fasciolosis in a mammal.  
WO/2024/048778A1
The present invention relates to an aryltetrahydropyridine compound represented by formula (1) or a salt thereof. [In formula (1), Q represents Q-1, etc.; J represents J-1, etc.; G represents G-1, etc.; R1 represents a halo(C1-C6)alkyl, ...  
WO/2024/042930A1
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventin...  
WO/2023/073641A9
This invention provides for compounds of the formula: (I) wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and/or prevention of a parasitic infesta...  
WO/2024/042112A1
The present invention provides antigen binding proteins such as antibodies targeting Plasmodium sporozoites, in particular Plasmodium circumsporozoite protein. The invention also provides nucleic acids that encode such antibodies. In add...  
WO/2024/038860A1
An onium salt of a nitrogen-containing (hetero)aryl compound according to the present invention is represented by formula (I) (in the formula, Q1 represents a pyrazole ring or the like, G1 represents a nitrogen or carbon atom, X1 represe...  
WO/2024/033281A1
The present invention relates to novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments as well as methods of their use and manufacture. Said compounds are particularly useful...  
WO/2024/033280A1
The present invention relates to novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments as well as methods of their use and manufacture. Said compounds are particularly useful...  
WO/2024/034948A1
Provided in the present invention are a composition and a method for preventing or treating scuticociliatosis in Paralichthys olivaceus, the composition containing micronized liquid sulfur as an active ingredient. The composition of the ...  
WO/2024/034565A1
Provided is a compound represented by formula (I-1a) or the like, or a salt thereof. [In formula (I-1a), R1 represents a substituted or unsubstituted C1-6 alkyl group, a substituted or unsubstituted C2-6 alkenyl group, or the like; R2 re...  
WO/2024/026301A1
The present disclosure relates to vaccines, therapeutic antibodies and methods of making such vaccines and antibodies. More specifically, the disclosure relates to methods of immunofocusing an immune response to a protein having both neu...  
WO/2024/026359A1
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...  
WO/2024/022910A1
The present invention relates to compounds of formula (I) wherein: X is O or S; Q is Qa or Qb as pesticides and insecticides. Preferred compounds are e.g. 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-di chloro-5-phenyl]urea ...  
WO/2024/020333A2
Disclosed is a class of kinase inhibitors. Related pharmaceutical compositions and methods of making and using the kinase inhibitors are also disclosed.  
WO/2022/251585A9
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Plasmodium parasitic antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administerin...  
WO/2024/011294A1
The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...  
WO/2024/003428A1
The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compo...  
WO/2024/003223A1
The present invention relates to a fucosylated saccharide, or a composition comprising a fucosylated saccharide, for use in preventing and/or treating a parasite infection in a subject, preferably cryptosporidiosis.  
WO/2024/005032A1
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...  
WO/2023/245258A1
This disclosure relates generally to the use of compounds that inhibit binding of Plasmodium cysteine-rich protective antigen (CyRPA) to glycans of cells that are susceptible to infection by Plasmodium pathogens, including glycans termin...  
WO/2023/248871A1
Provided are a compound represented by formula (I), etc. (wherein: Z represents an oxygen atom, etc.; R1, R2, R3 and R4 each independently represent a hydrogen atom or a substituted or unsubstituted C1-6 alkyl group; Y1 and Y2 each indep...  
WO/2023/243678A1
The present invention provides a pyrazole compound represented by formula (1) or a salt thereof, and a novel bactericide containing same as an active ingredient, particularly, a bactericide for agricultural and horticultural use. In the ...  
WO/2023/242070A1
The invention relates to phenylene diamine derivatives with certain pharmacological properties resulting from enhancement of epithelial barrier function and/or blocking bacterial translocation through the epithelial barrier. The compound...  
WO/2023/242598A1
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.  
WO/2023/239811A1
Provided herein are Endochin-Like Quinolone (ELQ) compounds of Formula (I): or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions comprising them and methods for their use in treating or preventing parasit...  
WO/2023/237795A1
The present invention relates to the use of an elatol compound for treating or preventing primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject. The invention also relates to the pharmaceutical...  
WO/2023/240045A1
Use of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), mavelertinib, as a treatment for giardiasis in humans, veterinary animals, and livestock is described. Mavelertinib demonstrates a high selectivity index f...  
WO/2023/232123A1
Provided are a sesquiterpene polyketone compound, a pharmaceutical composition, and use thereof as an immunomodulator and in preventing and treating immune diseases. Biological activity assay shows that the sesquiterpene polyketone compo...  
WO/2023/233413A1
Methods of inhibiting eIF4Gl binding to elFl, and inhibiting translation initiation are provided. Pharmaceutical compositions comprising inhibitors of eIF4Gl-eIFl binding and there use in treating disease are also provided.  
WO/2023/235480A1
Provided herein are aryl hydantoin compounds having the structure of Formula (I) wherein X, R1, R2, R3, R4, and n are described herein. Also provided herein are compositions comprising compounds of Formula (I) and methods of using compou...  
WO/2023/233200A1
This invention relates to a composition comprising: (a) a hydroalcoholic solution comprising a Quassia amara extract, wherein the solution comprises at least 80 %v/v of at least one alcohol, and (b) a vegetable oil. The invention also re...  
WO/2023/228257A1
The present invention addresses the problem of providing a novel anti-cryptosporidium drug. The present invention provides an anti-cryptosporidium drug containing at least one selected from the group consisting of bufotalin, cinobufotali...  
WO/2023/230217A1
Provided herein are antileishmanial compounds, compositions comprising the antileishmanial compounds, and use thereof.  
WO/2023/221862A1
Provided are an anti-parasitic infection external pharmaceutical formulation , a preparation method therefor and use thereof. The external pharmaceutical formulation comprises a first active ingredient and an aldehyde compound, the first...  
WO/2023/218194A1
The present invention concerns compounds suitable as RNA or DNA binders. RNA or DNA binders are useful in the treatment of various conditions, including those caused by microbial infection and cancer. The present invention concerns speci...  
WO/2023/220281A1
The present disclosure provides feed additive compositions and related methods for the treatment and prevention of coinfection with Clostridium bacteria and Eimeria protozoa. The feed additive compositions herein can include a microbial ...  
WO/2023/215819A2
Methods of reducing viability of a parasite in a subject involve administering an effective amount of an inhibitor of guanosine-5'-triphosphate cyclohydrolase I (GCH) to the subject. Methods of identifying an agent that reduces viability...  
WO/2023/213998A1
The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antig...  
WO/2023/209336A1
The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment ...  
WO/2023/209250A1
The present disclosure relates to a compound of the formula (6) or (7); or a pharmaceutically acceptable salt, ester, solvate thereof, for use in medicine, in particular for the use in treatment and therapy of malaria and leishmaniasis. ...  
WO/2023/211275A1
The present invention provides novel fusion polypeptides and compositions comprising the same. The fusion polypeptides are able to trigger and/or enhance an immune response against a peptide sequence of interest comprised therein and the...  
WO/2023/205272A1
The present application provides compounds and methods for treating various diseases such as malaria and cancer.  
WO/2023/205378A1
The natural product neurolenin D is isolated from Neurolaena lobata using continuous extraction, stirring over charcoal, flash column chromatography, and recrystallization. The secondary alcohol in this molecule is converted into a metha...  
WO/2023/202336A1
Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and/or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of dr...  

Matches 1 - 50 out of 12,835